

ANCO FAX News

Association of Northern California Oncologists
Post Office Box 151109, San Rafael, California 94915-1109
Voice: (415) 472-3960 • FAX: (415) 472-3961
execdir@anco-online.org • www.anco-online.org

Vol. 16, No. 20

November 3rd, 2017

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association* and membership news. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at www.anco-online.org/pubs.html.

In this issue:

- FDA on compassionate use & biosimilars
- ASCO working with FDA on IV fluid shortage
- *Multidisciplinary Management of Cancers*

The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts) Members. The next regular *ANCO FAX News* will be published on November 17th. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; execdir@anco-online.org.

The ANCO FAX News has information for every member of your practice or organization. Pass it along!

- Physician Members
- Nurses & Office Managers
- Office Staff
- Colleagues & Representatives

The Association of Northern California Oncologists (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge. The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues

The United States Food and Drug Administration (FDA) is changing its compassionate-use program, which gives seriously ill patients access to experimental drugs under FDA review, to grant access to more patients. The changes will streamline the compassionate-use program. The new process only requires approval from one designated member of an internal review board, such as the chair. The FDA also updated its industry guidance document to clarify how adverse events in compassionate-use patients should be reported. Learn more at www.ashclinicalnews.org/online-exclusive/fda-eases-restrictions-compassionate-use-program/.

The United States Food and Drug Administration (FDA) has created a series of educational materials to help health care professionals better understand biosimilars and interchangeable drugs. Access these materials at www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/ucm580435.htm.

CMS has released its proposed CY2018 Physician Fee Schedule (PFS) and Outpatient Prospective Payment System (OPPS) rules. Read the proposed rule at www.federalregister.gov/documents/2017/07/20/2017-14883/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment; read the fact sheet at

www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2017-Fact-Sheet-items/2017-07-13.html. Major changes include a reduction in payments to hospitals participating in 340B under OPSS. Overall, physician payment rates will increase by .31% in CY2018 compared to CY2017, including an estimated 1% increase for radiation oncology. Read Bobbi Buell's summary of the proposed rule at www.anco-online.org/BBMPFS2018Analysis.pdf. Read ASCO's comments on the proposed rules at www.asco.org/advocacy-policy/asco-in-action/cms-urged-ensure-fair-adequate-medicare-reimbursement-oncologists; read ASH's comments on the proposed rules at www.hematology.org/Advocacy/Testimony.aspx/; read ACCC's comments on the proposed OPSS and PFS rules at www.accc-cancer.org/advocacy/pdf/ACCC-CY-2018-OPSS-Proposed-Rule-Comment-Letter.pdf?_zs=bhddd1&_zl=5oSB4 and www.accc-cancer.org/advocacy/pdf/ACCC-CY-2018-PFS-Proposed-Rule-Comment-Letter.pdf?_zs=bhddd1&_zl=6oSB4, respectively.

The Medicare Quality Payment Program (QPP), established by the Medicare Access and CHIP Reauthorization Act (MACRA), began on January 1st. This year is a transition year meaning you can "pick your pace" when implementing QPP in your practice. CMS has posted new resources to the QPP website to help clinicians successfully participate in the first year of the QPP. The new resources focus on support for small practices and alternative payment models (APMs). Visit qpp.cms.gov for more information. In addition, CMS is now accepting hardship exceptions from the QPP for the 2017 reporting year based on insufficient internet connectivity, extreme and uncontrollable circumstances, and lack of control over the availability of certified EHR technology. Learn more at qpp.cms.gov/about/hardship-exception.

CMS has issued a proposed rule that would make changes in the second year of the QPP. The

proposed rule “aims to simplify the program, especially for small, independent, and rural practices.” Read the CMS fact sheet at qpp.cms.gov/docs/QPP_Proposed_Rule_for_QPP_Year_2.pdf; and, read Bobbi Buell’s analysis at www.anco-online.org/BBMIPS2018.pdf. ASCO submitted comments to CMS on the proposed rule arguing that its data show that the median financial penalty for oncology practices under the proposal would range from 14-23%, well beyond the CMS-envisioned 4% penalty. ASCO urged CMS to refrain from implementing such a policy at any point in time. In addition, ASCO urged CMS to implement multiple oncology-focused APMs, including its own PCOP model. Read ASCO’s comments at www.asco.org/sites/new-www.asco.org/files/content-files/QPP-2018-Proposed-Rule-Comments.pdf; read ASH’s comments at www.hematology.org/Advocacy/Testimony.aspx; read ACCC’s comments at www.accc-cancer.org/ACCCbuzz/accc-comments-to-cms-on-quality-payment-program-proposed-rule/?utm_source=ACCCConnect&utm_medium=email&utm_campaign=ACCCConnect091317&_zs=bhddd1&_zl=8oSB4.

ASCO’s Quality Oncology Practice Initiative (QOPI) Qualified Clinical Data Registry (QCDR) is available for CMS MIPS reporting. By using the QOPI QCDR for MIPS reporting, practices will be able to report in 2017 and 2018 to avoid cuts to Medicare reimbursements in 2019 and 2020. Express your interest in participating in the QOPI QCDR by e-mailing qopi@asoc.org. Once registration is officially open, practices will be contacted regarding the necessary steps to begin their on-boarding process. For more information, please visit www.instituteforquality.org/qopi/about/quality-reporting.

ASCO’s series of webinars to guide oncology practices to successful quality reporting are available at www.asco.org/macra > MACRA Webinar Series. **ASCO has developed a MACRA**

decision tree tool to help oncology practices find precise information on their QPP participation status at www.asco.org/practice-guidelines/billing-coding-reporting/macra-quality-payment-program/macra-practice-tools/determine-status. For more information and access to ASCO’s revamped QPP/MACRA toolkit, educational materials, and resources, go to www.asco.org/macra. ASH’s updated MACRA webpage is at www.hematology.org/Clinicians/7427.aspx. **ASH members can now sign up to report data for the Medicare MIPS through Healthmonix’s MIPSPRO, a 2017 Qualified MIPS Registry.** Learn more at healthmonix.com/mips-pro/.

ASH will host a webinar on MIPS and Reporting for MIPS on November 13th at 10AM. The webinar will provide a specialized MIPS reporting plan for hematologists. If you are interested in attending this webinar, then please e-mail Leslie Brady at lbrady@hematology.org.

The American Medical Association (AMA) has produced a new short video entitled *One Patient, One Measure, No Penalty: How to avoid a Medicare payment penalty with basic reporting.* The video and other AMA resources are available at www.ama-assn.org/qpp-reporting. **CMA’s Center for Economic Services (CES) has published an update to its MACRA preparation checklist entitled *MACRA: What Should I Do Now to Prepare?*** available at www.cmanet.org/macra. **Physicians in practices with 15 or fewer can receive free assistance to prepare and participate in the QPP through the *California Health Information Partnership & Services Organization (CalHIPSO).*** Contact CalHIPSO at www.hsag.com/calhipso (and see the supplement to this edition of the *ANCO FAX News*.)

ASCO is aware of the growing IV fluid shortage, along with other drugs in short supply. While over the past few years ongoing drug shortages have not generally risen to the critical levels that they did earlier this decade, ASCO is concerned that recently they have seen an upsurge in

shortages, including IV fluids, electrolytes, and some forms of morphine, among others. They are collecting information from around the country and will be meeting with the *United States Food and Drug Administration* to determine what solutions they have or are planning to resolve this problem. In the interim, the *American Society of Health-System Pharmacists* and the *University of Utah Drug Information Service* have developed a document with suggestions for management and conservation of small-volume parenteral solutions (SVPs) at www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM582461.pdf.

CMS, in its final rule on the 2018 HOPSS, has finalized a proposal to cut reimbursement for separately paid drugs under the 340B Drug Pricing Program from ASP plus 6% to ASP minus 22.5%. Rural Sole Community Hospitals, PPS-exempt Cancer Hospitals, and Children's hospitals will be exempt from this policy in 2018. In addition, CMS finalized proposed revisions to the 14-day rule for molecular pathology and advanced diagnostic laboratory tests.

USP has announced that it will postpone the official date of General Chapter 800 (i.e., USP800) to December 1st, 2019. USP800 was originally scheduled to become office on July 1st, 2018. USP now plans to align the official date of USP800 with the release of the final version of USP797. However, some state and national enforcement agencies and other entities may require adherence to USP800 before its official implementation date.

CMA, MOASC, and State Legislative & Regulatory Issues

The *California Medical Association* (CMA) has published its 2017 legislative wrap-up entitled *Unwavering Defense*. The wrap-up is available to CMA members at www.cmanet.org/resource-library/detail/?item=legislative-wrap-up-2017.

Sacramento can be a dangerous place for doctors. Many bills impacting medicine wind their way

through the *Capitol* on their journey to the *Governor's* desk. And, many of these bills threaten the medical profession with the backing of powerful lobbyists and PACs. It's critical that **physicians have an advocate at work for them every day and who knows how to speak on their behalf. That advocate is the *California Medical Association* (CMA).** While physicians keep a close eye on their patients, CMA is keeping a close eye on those bills...and more. **Got payment delays? Feeling victimized by payers and overwhelmed by the process? Don't let the health plans mistreat you. The CMA's *Center for Economic Services* (CES) has a team of reimbursement specialists available to assist ANCO's CMA members experiencing payment problems with third-party payers.** For membership, please call (916) 551-2042; for reimbursement assistance, please call CMA's *Reimbursement Helpline* at (888) 401-5911.

CMA Practice Resources* (CPR) is a monthly e-mail bulletin from CMA's *Center for Economic Services that is full of tips and tools to help physicians and their office staff improve practice efficiency and viability. Subscribing to CPR is free and open to anyone, but CMA membership is necessary to access the resources, toolkits, forms, and tools that are located on the members-only CMA website. Please visit www.cmanet.org/cpr to subscribe.

Noridian/JEMAC, DHCS/MediCal, & Private Payers

***Noridian Administrative Services* is the Jurisdiction E (JE) *Medicare Administrative Contractor* (MAC).** Jurisdiction E includes California. Regularly review postings at the *Noridian/JEMAC* website at med.noridianmedicare.com/web/jeb. Recent updates include:

- MLN Connects Provider eNews *Announcements*—New Medicare Numbers/Cards: Coordination of Benefits; MIPS: Participate in Field Testing of Episode-Based Cost Measures

by November 15; Physician Compare Preview Period Extended to December 1; Reporting Changes in Ownership-Reminder; New Medicare Card: Provider Ombudsman Announced; CMS Offers Medicare Enrollment Relief for Americans Affected by Recent Disasters *Publications*—Quality Payment Program in 2017: MIPS APMs Web-Based Training Course-New; General Equivalence Mappings FAQs Booklet-Revised; Medicare Fraud & Abuse: Prevention, Detection, and Reporting Web-Based Training Course-Reminder; QRUR Webcast: Audio Recording and Transcript-New; ICD-10-CM/PCS the Next Generation of Coding Booklet-Revised; Diagnosis Coding: Using the ICD-10-CM Web-Based Training Course-Reminder; Medicare Home Health Benefit Web-Based Training Course-Reminder; SNF Billing Reference Booklet-Reminder; Items and Services Not Covered under Medicare Booklet-Reminder

- MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease LCD-R5
- Medicare FFS Response to the 2017 California Wildfires SE17035
- Clinical Laboratory Fee Schedule Not Otherwise Classified, Not Otherwise Specified or Unlisted Service or Procedure Code Data Collection CR10232
- MSP Payment Calculator Now Offers Enhanced Details
- MolDX: Bladder Tumor Marker FISH Billing and Coding Guidelines-R2
- DecisionDX-UM Billing Guidelines Article Retirement-Effective September 22, 2017

- MolDX: AlloSure Donor-Derived Cell-Free DNA Test Final LCD-Effective December 11, 2017

Forthcoming *Noridian/JEMAC* meetings/webinars/workshops include:

- Modifier 59, NCCI and MUE Webinar (November 29)

Visit med.noridianmedicare.com/web/job/education/training-events for more information and to register.

CMS has published a MLN Matters article entitled *Medicare Fee-for-Service (FFS) Response to the 2017 California Wildfires* at www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/downloads/SE17035.pdf.

***Anthem Blue Cross* will conduct post-payment coding reviews of professional claims billed with modifiers 25, 62, 80, 81, 82, AS, and 91 beginning in 4Q2017. Additionally, *Anthem* will conduct post-payment coding reviews of E&M services billed during a global surgery period. If you have questions, please contact CAContractSupport@anthem.com.**

***Anthem Blue Cross* has announced that it is launching *IngenioRx*, a new pharmacy benefits manager (PBM). *IngenioRx* will begin offering a full suite of PBM solutions starting in 2020. Learn more at image.messageinsite.com/lib/fe5c15707d600d78751c/m/1/101717_NEW-PBM-RELEASE.pdf.**

***UnitedHealthcare's Network Bulletin* (November 2017) is now available online at www.unitedhealthcareonline.com > Tools & Resources > News & Network Bulletin and features articles on opioid guidance and resources, *Network Bulletin* revisions that include article summaries and easier navigation, improvements to the Provider Administrative Guides, and new prior authorization and notification app will be fully deployed.**

EDUCATION

[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

ANCO's 2017 Hematologic Malignancies Updates

ANCO is organizing a series of *Hematologic Malignancies Updates* in 2017. The third and final *Update* takes place on November 4th at the *San Francisco Hyatt Regency* with Mehrdad Abedi, M.D., *University of California, Davis*, Sandy W. Wong, M.D., *University of California, San Francisco*, and Leena T. Rahmat, M.D., *University of California, San Francisco*. The latest research on novel treatment modalities for hematologic malignancies, myeloma, and amyloidosis, along with case studies for these diagnoses will be presented. These updates are supported by *Janssen Oncology*, *Merck*, *Pfizer Oncology*, and *Pharmacyclis*. Download the meeting announcement at www.anco-online.org/4Q2017HemeMaligUpdate.pdf.

SAVE THE DATE 18th Multidisciplinary Management of Cancers: A Case-based Approach

The *18th Multidisciplinary Management of Cancers: A Case-based Approach* returns to the *Silverado Resort and Spa* in Napa on March 16-18th. The meeting is sponsored by the *Association of Northern California Oncologists*, *Stanford Cancer Institute*, *UC Davis Comprehensive Cancer Center*, and the *UCSF Helen Diller Family Comprehensive Cancer Center*. Go to www.multicancers.org for more information including registration and housing.

Additional Education Meetings

November 8th
Advances in the Treatment of HER2 Positive Breast Cancer
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

November 11th
Best of WCLC 2017-San Francisco
International Association for the Study of Lung Cancer
San Francisco
(www.eventbrite.com/e/best-of-the-18th-wclc-san-francisco-tickets-37865231928)

November 11th
2nd Annual Symposium on Integrating Immune Therapies & Targeted Therapies into Standards of Care for Solid and Hematologic Malignancies
Global Resource for Advancing Cancer Education
San Francisco

November 14th
Update on Mantle Cell Lymphoma
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

November 15th
Mind Body Techniques to Cope with the Stresses of Cancer
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

November 29th
Advances in the Treatment of Triple Negative Breast Cancer (Part I of Living with Triple Negative Breast Cancer)
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

November 30th
Coping with the Stresses of Caregiving When Your Loved One Has Triple Negative Breast Cancer (Part II of Living with Triple Negative Breast Cancer)
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

December 14th
Update on Chronic Lymphocytic Leukemia (CLL)
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

December 20th
Update on Clinical Trials & Triple Negative Breast Cancer (Part III of Living with Triple Negative

Breast Cancer)

CancerCare Connect Education Workshop
(www.cancer.org/connect_workshops)

Please contact the ANCO office for more information about these meetings.

ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS

[Editor's Note: All ANCO members are also eligible for several tangible benefits.]

Annual Election

Four seats on the ANCO Board of Directors are up for election in 2017. ANCO seeks nominations for candidates for these seats. This year's election will be conducted via mail ballot in December. Candidates with the top four vote totals will serve for three years (i.e., from 2018-2020, inclusive). Nominate an ANCO member (including yourself) to stand for election to the *Board* via e-mail/FAX to the ANCO office at execdir@anco-online.org/(415) 472-3961.

Board of Directors

The ANCO Board of Directors teleconferenced on October 26th to discuss and/or act upon the following:

- California legislation
- ANCO rebranding proposals
- By-Laws amendment
- 2017 Annual Election

Contact the ANCO office for additional information on any of these items. The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The **next regularly scheduled ANCO Board of Directors meeting is scheduled for December 12th**. Please call José Luis González, *ANCO Executive Director*, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

Individual Member News

The ASCO Nominating Committee has selected 16 distinguished ASCO members as candidates for open leadership positions within the Society. Detailed information on candidates for open positions, including a community oncology seat, is now available at www.asco.org/about-asco/asco-overview/asco-election?. Eligible ASCO members may vote through December 4th.

Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO *Board* believes that the *Association* and *The Permanente Medical Group* (TPMG) will each receive value from Group Membership.

ANCO initiated a **Multi Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Diablo Valley Oncology & Hematology Medical Group*, *EPIC Care*, *Marin Cancer Care*, *Pacific Cancer Care*, and *Palo Alto Medical Foundation* for their multi site group memberships.

Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to

provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

*AbbVie • Agendia • Agios Pharmaceuticals
Alexion Pharmaceuticals
AMGEN • ARIAD Pharmaceuticals
Astellas Oncology • AstraZeneca
Bayer Healthcare Pharmaceuticals
bioTheranostics
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb Oncology
Cardinal Health Specialty Solutions
Celgene • Clovis Oncology • Daiichi Sankyo
Eisai • EMD Serono • Exelixis
Foundation Medicine • Genentech BioOncology
Genomic Health • Gilead Sciences
Guardant Health • Helsinn Oncology
Heron Therapeutics • Incyte
Janssen Oncology • Jazz Pharmaceuticals
Kite Pharmaceuticals • Lilly Oncology • Merck
nanoString • Novartis Oncology
Oncology Supply/ION • Pfizer Oncology
Pfizer US Biosimilars • Pharmacyclics
Puma Biotechnology • Sandoz Biopharmaceuticals
Sanofi Genzyme • Seattle Genetics
Taiho Oncology • Takeda Oncology
TerSera Therapeutics • Tesaro
TEVA Oncology*

We especially wish to thank and welcome *Agendia, Agios Pharmaceuticals, bioTheranostics, EMD Serono, Kite Pharmaceuticals, Pfizer US Biosimilars, Puma Biotechnology, and TerSera Therapeutics* as new Corporate Members for 2017. *Dendreon, Genoptix Medical Laboratory, GenPath Oncology, Infinity Pharmaceuticals, Ipsen Biopharmaceuticals, Medivation, Merrimack Pharmaceuticals, and Prometheus Laboratories* did not renew their memberships for 2017. Please visit www.anco-online.org/assistance.html for **Corporate Member drug reimbursement and patient assistance program information**. ANCO encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

CORRECTION *AstraZeneca* informs ANCO that the Tagrisso is indicated for the treatment of

patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed after EGFR tyrosine kinase inhibitor therapy.

AstraZeneca informs ANCO that the *United States Food and Drug Administration* has approved Calquence as a treatment for adults with mantle cell lymphoma who have received at least one prior therapy.

Merck informs ANCO that the *United States Food and Drug Administration* has approved Keytruda for use in patients with advanced gastric (stomach) cancer that is PD-L1 positive.

Pfizer Oncology has implemented emergency relief protocols at *Pfizer RxPathways* to ensure that patients impacted by the northern California wildfires have continued access to their *Pfizer* medicines. If a medicine provided through a *Pfizer* patient assistance program has been destroyed or lost, or patients who are enrolled are unable to reach their doctors' offices and need their medicine shipped to an alternate location, *Pfizer* can arrange for early refills and/or new shipping addresses. If new patients urgently need a *Pfizer* medicine but have been displaced and are unable to access income documentation and other paperwork needed for enrollment into the program, *Pfizer* is able to waive these requirements so that patients can receive their medication as quickly as possible. Facilities that participate in *Pfizer's* bulk replenishment Institutional Patient Assistance Program can request early replenishment of the *Pfizer* medicines covered or request additional inventory to meet increased demand. For help with *Pfizer's* oncology medicines, call *Pfizer Oncology Together* directly at (877) 744-5675; for help with other *Pfizer* medicines, call *Pfizer RxPathways* at (844) 989-PATH (7284).

Tesaro informs ANCO that the *United States Food and Drug Administration* has approved

Varubi IV for delayed nausea and vomiting associated with cancer chemotherapy.

Publications, Resources, Services, & Surveys

The ASCO Guidelines App is your go-to tool for implementing guideline recommendations into practice. This user-friendly app provides health care providers, patients, and caregivers with the recommended cancer care options for a variety of cancer types. It also includes interactive tools to inform treatment decisions at the point of care, thus increasing the quality of care provided to patients. The app is free to members and nonmembers, kept up to date, and will continue to grow as more guidelines and tools are added. Download the app at www.asco.org/guidelines or www.asco.org/apps.

ASCO's *Clinical Affairs Department* provides services, education, and resources to support oncology practices. It offers hands-on assistance in areas such as practice management, quality care assessment and improvement, and efficiency and business intelligence to meet the needs and demands of the current oncology landscape. Resources on the business of oncology, practice management (staffing, technology), practice transformation, and market analysis are available from the *Department*. For more information, visit www.asco.org/practice-guidelines/practice-support.

ASCO's 2018 *Quality Training Program*, a comprehensive program designed to train oncology health care providers to investigate and implement data-driven quality improvement and manage clinical and non-clinical processes and outcomes, will take place in two locations—Miami and Alexandria. To learn more about and apply to participate in the *Program*, visit www.asco.org/training-education/professional-development/quality-training-program.

ASCO is launching its new *Practice Engagement Program* to help administrators, physicians, and other members of the care team navigate ASCO tools, programs, and resources available to help

oncology practices respond to the changes occurring in the cancer care delivery system.

Building on an array of resources developed to help practices remain viable and thrive during this turbulent period, the new *Practice Engagement Team* will help participating practices learn more about the specific ASCO services and programs that can best support their needs. Learn more at www.asco.org/advocacy-policy/asco-in-action/new-practice-engagement-program-connects-practices-specific-resources.

Registration is now open for the QOPI Fall Round that ends on November 7. For more information, visit www.asco.org/advocacy-policy/asco-in-action/2017-qopi-fall-round-closes-november-07.

ACCC's *Optimizing Electronic Health Records Project* identifies real-world tactics for overcoming common challenges and barriers to efficient EHR use. As part of that Project, ACCC's new 16-page *Optimizing your EHR* report highlights key findings with real-world experiences with EHR implementation and use across community cancer programs and practices. Read the report at www.informz.net/ACCC/data/images/Attachments/EHR-Publication.PDF.

NCCN has published and/or updated their *Chemotherapy Order Templates, Clinical Practice Guidelines in Oncology, Drugs & Biologics Compendium, Evidence Blocks, Guidelines for Patients, Imaging Appropriate Use Criteria, and/or Radiation Therapy Compendium* for acute lymphoblastic leukemia (V5.2017), adult cancer pain (V2.2017), cervical cancer (V1.2018), chronic lymphocytic leukemia/small lymphocytic lymphoma (V2.2018), chronic myeloid leukemia (V2.2018), hairy cell leukemia (V2.2018), hepatobiliary cancers (V4.2017), melanoma (V1.2018), non-small cell lung cancer (V9.2017), uterine neoplasms-endometrial carcinoma (V1.2018), vulvar cancer (V1.2018). Go to www.nccn.org for more information.